More than 130 suppliers

In-house tech support

Call +31 (0)26 326 44 50

Bio-Connect

Products
Products
Antibodies
Chemicals
Proteins / Signaling Molecules
Assays
DNA / RNA / Vectors
Cell Culture
Genome Editing and Engineering
Molecular Biology
Lysates / Extracts
Expression
Labware / Accesories
Body Products
Technique Specific Products
Arrays / Slides
All product groups
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Research
Research
Cancer research
Epigenetics research
Immunology and inflammation research
Neuroscience research
Virology research
SARS-CoV-2
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Industries
Suppliers

Tech support
News
About us
About us
Our company
Our people
Divisions
Vacatures
Events
Promotions
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
FAQ
Contact

ProductsBack/Roscovitine [186692-46-6]

Roscovitine [186692-46-6]

R5774

Estimated Purity≥98%

DownloadDatasheet

Product group Chemicals

Overview

Supplier
LKT Laboratories
Product Name
Roscovitine [186692-46-6]
Delivery Days Customer
7
Estimated Purity
≥98%
Format
Soluble in DMSO or chloroform.
Scientific Description
CDK inhibitor, L-type Ca2+ channel blocker.; Seliciclib, CYC202
Storage Instruction
-20°C
UNSPSC
12352200

References

Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol. 2009 Oct;158(4):1004-16. PMID: 19775281. Yarotskyy V, Elmslie KS. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br J Pharmacol. 2007 Oct;152(3):386-95. PMID: 17700718. Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007 Jan;48(1):158-67. PMID: 17325859.